Active surveillance for prostate cancer: Past, present and future

Current Opinion in Oncology

Volumn 24, Issue 3, 2012, Pages 243-250

  Singer, Eric A ^a   Kaushal, Aradhana ^a   Turkbey, Baris ^b   Couvillon, Anna ^b   Pinto, Peter A ^a   Parnes, Howard L ^c  

^a Center for Cancer Research   (United States)

^b Cancer Research Center   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

active surveillance; focal ablation; multiparametric MRI; prostate cancer; prostate specific antigen; screening; watchful waiting

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER;

ABLATION THERAPY; BOWEL TOXICITY; CANCER EPIDEMIOLOGY; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER RISK; CANCER SCREENING; CANCER SURGERY; CANCER THERAPY; CHEMOPROPHYLAXIS; DISEASE ASSOCIATION; ERECTILE DYSFUNCTION; HUMAN; IMAGE ANALYSIS; MEDICAL RESEARCH; PATIENT MONITORING; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE; REVIEW; TOXICITY; TREATMENT OUTCOME; URINE INCONTINENCE;

EARLY DIAGNOSIS; ERECTILE DYSFUNCTION; HUMANS; MALE; PATIENT SELECTION; POPULATION SURVEILLANCE; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; QUALITY OF LIFE; TUMOR MARKERS, BIOLOGICAL; WATCHFUL WAITING;

EID: 84859843062     PISSN: 10408746     EISSN: 1531703X     Source Type: Journal    
DOI: 10.1097/CCO.0b013e3283527f99     Document Type: Review

References (68)

1. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011; 61:69-90.
2. Siegel R, Ward E, Brawley O, et al. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011; 61:212-236.
3. de Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011; 364:1995-2005.
4. de Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010; 376:1147-1154.
5. Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010; 363:411-422.
6. Alemozaffar M, Regan MM, Cooperberg MR, et al. Prediction of erectile function following treatment for prostate cancer. JAMA 2011; 306:1205-1214.
7. Sanda MG, Dunn RL, Michalski J, et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med 2008; 358:1250-1261. (Pubitemid 351439226)
8. Shibata A, Ma J, Whittemore AS. Prostate cancer incidence and mortality in the United States and the United Kingdom. J Natl Cancer Inst 1998; 90:1230-1231. (Pubitemid 28407090)
9. Lu-Yao G, Albertsen PC, Stanford JL, et al. Natural experiment examining impact of aggressive screening and treatment on prostate cancer mortality in two fixed cohorts from Seattle area and Connecticut. BMJ 2002; 325:740-745.
10. Bartsch G, Horninger W, Klocker H, et al. Prostate cancer mortality after introduction of prostate-specific antigen mass screening in the Federal State of Tyrol, Austria. Urology 2001; 58:417-424. (Pubitemid 32816361)
11. Concato J, Wells CK, Horwitz RI, et al. The effectiveness of screening for prostate cancer: a nested case-control study. Arch Intern Med 2006; 166:38-43. (Pubitemid 43063839)
12. Kopec JA, Goel V, Bunting PS, et al. Screening with prostate specific antigen and metastatic prostate cancer risk: a population based case-control study. J Urol 2005; 174:495-499; discussion 499. (Pubitemid 40981582)
13. Labrie F, Candas B, Dupont A, et al. Screening decreases prostate cancer death: first analysis of the 1988 Quebec prospective randomized controlled trial. Prostate 1999; 38:83-91. (Pubitemid 29052946)
14. Andriole GL, Crawford ED, Grubb RL 3rd, et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009; 360:1310-1319.
15. Andriole GL, Crawford ED, Grubb RL 3rd, et al. Prostate Cancer Screening in the Randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: Mortality Results after 13 Years of Follow-up. J Natl Cancer Inst 2012; 104:125-132.
16. Schroder FH, Hugosson J, Roobol MJ, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009; 360:1320-1328.
17. Gulati R, Mariotto AB, Chen S, et al. Long-term projections of the harm-benefit trade-off in prostate cancer screening are more favorable than previous shortterm estimates. J Clin Epidemiol 2011; 64:1412-1417.
18. Hugosson J, Carlsson S, Aus G, et al. Mortality results from the Goteborg randomised population-based prostate-cancer screening trial. Lancet Oncol 2010; 11:725-732.
19. Lin K, Croswell JM, Koenig H, et al. Prostate-specific antigen-based screening for prostate cancer: an evidence update for the U.S. Preventive Services Task Force, U.S.D.o.H.a.H. Services. Rockville: Agency for Healthcare Research and Quality; 2011. pp. 1-56.
20. Calonge N, Petitti DB, DeWitt TG, et al. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2008; 149:185-191.
21. NIH, National Institutes of Health State-of-the-Science Conference: Role of Active Surveillance in the Managment of Men with Localized Prostate Cancer, U.S.D.o.H.a.H. Services. Bethesda: National Center for Biotechnology Information (US); 2011. pp. 1-127.
22. Bill-Axelson A, Holmberg L, Ruutu M, et al. Radical prostatectomy versus watchful waiting in early prostate cancer.N Engl J Med 2011;364:1708-1717.
23. Wilt TJ, Brawer MK, Barry MJ, et al. The prostate cancer intervention versus observation trial:VA/NCI/AHRQ cooperative studies program #407 (PIVOT): design and baseline results of a randomized controlled trial comparing radical prostatectomy to watchful waiting for men with clinically localized prostate cancer. Contemp Clin Trials 2009; 30:81-87.
24. Lane JA, Hamdy FC, Martin RM, et al. Latest results from the UK trials evaluating prostate cancer screening and treatment: the CAP and ProtecT studies. Eur J Cancer 2010; 46:3095-3101.
25. Harlan SR, Cooperberg MR, Elkin EP, et al. Time trends and characteristics of men choosing watchful waiting for initial treatment of localized prostate cancer: results from CaPSURE. J Urol 2003; 170:1804-1807. (Pubitemid 37254932)
26. Lawrentschuk N, Klotz L. Active surveillance for low-risk prostate cancer: an update. Nat Rev Urol 2011; 8:312-320.
27. Shappley WV 3rd, Kenfield SA, Kasperzyk JL, et al. Prospective study of determinants and outcomes of deferred treatment or watchful waiting among men with prostate cancer in a nationwide cohort. J Clin Oncol 2009; 27:4980-4985.
28. Cuzick J, Fisher G, Kattan MW, et al. Long-term outcome among men with conservatively treated localised prostate cancer. Br J Cancer 2006; 95:1186-1194. (Pubitemid 44658482)
29. Klotz L. Active surveillance for prostate cancer: a review. Curr Urol Rep 2010; 11:165-171.
30. Steineck G, Helgesen F, Adolfsson J, et al. Quality of life after radical prostatectomy or watchful waiting. N Engl J Med 2002; 347:790-796. (Pubitemid 34988337)
31. Hayes JH, Ollendorf DA, Pearson SD, et al. Active surveillance compared with initial treatment for men with low-risk prostate cancer: a decision analysis. JAMA 2010; 304:2373-2380.
32. Smith MR. Effective treatment for early-stage prostate cancer-possible, necessary, or both? N Engl J Med 2011; 364:1770-1772.
33. Barry MJ. Health decision aids to facilitate shared decision making in office practice. Ann Intern Med 2002; 136:127-135. (Pubitemid 34073937)
34. Klotz L, Zhang L, Lam A, et al. Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol 2010; 28:126-131.
35. D'Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998; 280:969-974. (Pubitemid 28445094)
36. Tosoian JJ, Trock BJ, Landis P, et al. Active surveillance program for prostate cancer: an update of the Johns Hopkins experience. J Clin Oncol 2011; 29:2185-2190.
37. Bastian PJ, Mangold LA, Epstein JI, et al. Characteristics of insignificant clinical T1c prostate tumors. A contemporary analysis. Cancer 2004; 101:2001-2005. (Pubitemid 39425375)
38. Lee MC, Dong F, Stephenson AJ, et al. The Epstein criteria predict for organconfined but not insignificant disease and a high likelihood of cure at radical prostatectomy. Eur Urol 2010; 58:90-95.
39. Cooperberg MR, Cowan JE, Hilton JF, et al. Outcomes of active surveillance for men with intermediate-risk prostate cancer. J Clin Oncol 2011; 29:228-234.
40. Hadway P, Barrett LK, Waghorn DJ, et al. Urosepsis and bacteraemia caused by antibiotic-resistant organisms after transrectal ultrasonography-guided prostate biopsy. BJU Int 2009; 104:1556-1558.
41. Loeb S, Carter HB, Berndt SI, et al. Complications after prostate biopsy: data from SEER-Medicare. J Urol 2011; 186:1830-1834.
42. Turkbey B, Albert PS, Kurdziel K, et al. Imaging localized prostate cancer: current approaches and new developments. AJR Am J Roentgenol 2009; 192:1471-1480.
43. Choo R, Klotz L, Danjoux C, et al. Feasibility study: watchful waiting for localized low to intermediate grade prostate carcinoma with selective delayed intervention based on prostate specific antigen, histological and/or clinical progression. J Urol 2002; 167:1664-1669. (Pubitemid 34240696)
44. Vickers AJ, Savage C, O'Brien MF, et al. Systematic review of pretreatment prostate-specific antigen velocity and doubling time as predictors for prostate cancer. J Clin Oncol 2009; 27:398-403.
45. Raz O, Haider M, Trachtenberg J, et al. MRI for men undergoing active surveillance or with rising PSA and negative biopsies. Nat Rev Urol 2010; 7:543-551.
46. Ross AE, Loeb S, Landis P, et al. Prostate-specific antigen kinetics during follow-up are an unreliable trigger for intervention in a prostate cancer surveillance program. J Clin Oncol 2010; 28:2810-2816.
47. Cooperberg MR, Carroll PR, Klotz L. Active surveillance for prostate cancer: progress and promise. J Clin Oncol 2011; 29:3669-3676.
48. Porten SP, Whitson JM, Cowan JE, et al. Changes in prostate cancer grade on serial biopsy in men undergoing active surveillance. J Clin Oncol 2011; 29:2795-2800.
49. Choo R, Danjoux C, Morton G, et al. How much does Gleason grade of followup biopsy differ from that of initial biopsy in untreated, Gleason score 4-7, clinically localized prostate cancer? Prostate 2007; 67:1614-1620. (Pubitemid 350036947)
50. Freedland SJ, Kane CJ, Amling CL, et al. Upgrading and downgrading of prostate needle biopsy specimens: risk factors and clinical implications. Urology 2007; 69:495-499. (Pubitemid 46428381)
51. Suardi N, Capitanio U, Chun FK, et al. Currently used criteria for active surveillance in men with low-risk prostate cancer: an analysis of pathologic features. Cancer 2008; 113:2068-2072.
52. Ploussard G, Durand X, Xylinas E, et al. Prostate cancer antigen 3 score accurately predicts tumour volume and might help in selecting prostate cancer patients for active surveillance. Eur Urol 2011; 59:422-429.
53. Auprich M, Chun FK, Ward JF, et al. Critical assessment of preoperative urinary prostate cancer antigen 3 on the accuracy of prostate cancer staging. Eur Urol 2011; 59:96-105.
54. Auprich M, Haese A, Walz J, et al. External validation of urinary PCA3-based nomograms to individually predict prostate biopsy outcome. Eur Urol 2010; 58:727-732.
55. Rubin MA, Maher CA, Chinnaiyan AM. Common gene rearrangements in prostate cancer. J Clin Oncol 2011; 29:3659-3668.
56. Pinto PA, Chung PH, Rastinehad AR, et al. Magnetic resonance imaging/ultrasound fusion guided prostate biopsy improves cancer detection following transrectal ultrasound biopsy and correlates with multiparametric magnetic resonance imaging. J Urol 2011; 186:1281-1285.
57. Turkbey B, Mani H, Shah V, et al. Multiparametric 3T prostate magnetic resonance imaging to detect cancer: histopathological correlation using prostatectomy specimens processed in customized magnetic resonance imaging based molds. J Urol 2011; 186:1818-1824.
58. Turkbey B, Bernardo M, Merino MJ, et al. MRI of localized prostate cancer: coming of age in the PSA era. Diagn Interv Radiol 2012; 18:34-45.
59. Lawrentschuk N, Haider MA, Daljeet N, et al. 'Prostatic evasive anterior tumours': the role of magnetic resonance imaging. BJU Int 2010; 105:1231-1236.
60. Rastinehad AR, Baccala AA Jr, Chung PH, et al. D'Amico risk stratification correlates with degree of suspicion of prostate cancer on multiparametric magnetic resonance imaging. J Urol 2011; 185:815-820.
61. Turkbey B, Xu S, Kruecker J, et al. Documenting the location of systematic transrectal ultrasound-guided prostate biopsies: correlation with multiparametric MRI. Cancer Imaging 2011; 11:31-36.
62. Albertsen PC, Hanley JA, Barrows GH, et al. Prostate cancer and the Will Rogers phenomenon. J Natl Cancer Inst 2005; 97:1248-1253. (Pubitemid 41535365)
63. Hou AH, Sullivan KF, Crawford ED. Targeted focal therapy for prostate cancer: a review. Curr Opin Urol 2009; 19:283-289.
64. NCI. MR Image Guided Therapy in Prostate Cancer. (2011) http://www.clini caltrials.gov/ct2/show/NCT01377753?term1/4prostate +cancer +ablation& recr1/4Open&no-unk1/4Y&type1/4Intr&state11/4NA%3AUS%3AMD&rank1/ 4 2.
65. Sporn MB, Suh N. Chemoprevention of cancer. Carcinogenesis 2000; 21:525-530. (Pubitemid 30137938)
66. Fleshner N, Lucia MS, Melich K, et al. Effect of dutasteride on prostate cancer progression and cancer diagnosis on rebiopsy in the REDEEM active surveillance study. J Clin Oncol 2011; 29(Suppl 7):Abstract 2.
67. Klotz L. Active surveillance for prostate cancer: for whom? J Clin Oncol 2005; 23:8165-8169. (Pubitemid 46211550)
68. Warlick C, Trock BJ, Landis P, et al. Delayed versus immediate surgical intervention and prostate cancer outcome. J Natl Cancer Inst 2006; 98:355-357. (Pubitemid 43338215)